Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment beyond progression by adding bevacizumab to XELOX or FOLFOX in metastatic colorectal cancer
2009-012090-36Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in metastatic colon cancer (mCRC), sponsored by Roche. Primary endpoints: Progression-free survival (PFS) on treatment beyond progression therapy and Progression-free survival (PFS) from start of first-line therapy. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2009-012090-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012090-36.